ValuEngine upgraded shares of Harrow Health (NASDAQ:HROW) from a sell rating to a hold rating in a report published on Monday morning, ValuEngine reports.

Several other research firms have also weighed in on HROW. Zacks Investment Research upgraded Harrow Health from a sell rating to a buy rating and set a $6.00 price objective on the stock in a research note on Friday, March 15th. TheStreet upgraded Harrow Health from a d- rating to a c rating in a research note on Wednesday, May 1st.

HROW stock opened at $5.30 on Monday. Harrow Health has a 1-year low of $1.99 and a 1-year high of $7.20. The company has a market capitalization of $141.28 million, a PE ratio of 8.69 and a beta of -0.02. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.22 and a current ratio of 3.43.

Harrow Health (NASDAQ:HROW) last released its quarterly earnings data on Tuesday, March 12th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.07). Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The company had revenue of $11.38 million during the quarter, compared to the consensus estimate of $10.92 million. Analysts forecast that Harrow Health will post -0.1 earnings per share for the current year.

In other news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $4.77, for a total value of $47,700.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 30,000 shares of company stock worth $162,500. Corporate insiders own 12.43% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Birchview Capital LP bought a new stake in Harrow Health during the 1st quarter worth approximately $896,000. BlueCrest Capital Management Ltd bought a new stake in Harrow Health during the 1st quarter worth approximately $125,000. JPMorgan Chase & Co. bought a new stake in Harrow Health during the 1st quarter worth approximately $168,000. Citigroup Inc. bought a new stake in Harrow Health during the 1st quarter worth approximately $92,000. Finally, Marshall Wace LLP bought a new stake in Harrow Health during the 1st quarter worth approximately $1,104,000. Institutional investors and hedge funds own 24.18% of the company’s stock.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

See Also: Why is total return important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.